$RPRX News
Last published 1w ago
- 1w agoRPRXRoyalty Pharma plc - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoRPRXRoyalty Pharma reports third quarter 2026 resultsGlobeNewswirePortfolio Receipts growth of 9% to $890 million; Royalty Receipts growth of 9%Net cash provided by operating activities of $686 millionRaised full year 2026 guidance: Portfolio Receipts expected to be $3,500 million to
- 3w agoRPRXRoyalty Pharma declares fourth quarter 2026 dividendGlobeNewswireNEW YORK, Oct. 16, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (NASDAQ:RPRX) has approved the payment of a dividend for the fourth quarter of 2026 of $0.235 per Class A ordinary share. The
- 1mo agoRPRXRoyalty Pharma to announce third quarter 2026 financial results on November 4, 2026GlobeNewswireNEW YORK, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will report its third quarter 2026 financial results on Wednesday, November 4, 2026 before the U.S. financial
- 1mo agoRPRXRoyalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration ProgramGlobeNewswireNEW YORK and WASHINGTON, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma and Blood Cancer United today announced a $7.5 million donation from Royalty Pharma to support Blood Cancer United’s Therapy Acceleration
- 1mo agoRPRXMorgan Stanley 24th Annual Global Healthcare Conference - ROYALTY PHARMA PLCEarnings Call TranscriptsOkay, great. Thanks for joining us, everybody. I'm Terrence Flynn, Morgan Stanley's U.S. Biopharma Analyst. For important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.com ba
- 2mo agoRPRXRoyalty Pharma to present at upcoming investor conferencesGlobeNewswireNEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September: Morgan Stanley 24th
- 2mo agoRPRXRoyalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsenGlobeNewswireNEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced an update on Novartis’ Phase 3 results from the HORIZON outcomes trial for pelacarsen, an antisense oligonucleotide studied
- 3mo agoRPRXRoyalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 millionGlobeNewswireNEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced an agreement for $100 million in funding to Zealand Pharma in exchange for Zealand Pharma’s economics related to rusfertide
- 3mo agoZEALRPRXZealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertideGlobeNewswireCompany announcement – No. 38 / 2026 Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide Zealand Pharma will receive USD 100
- 3mo agoRPRXRoyalty Pharma Q2 2026 Earnings Conference Call - ROYALTY PHARMA PLCEarnings Call TranscriptsThis video tutorial shows how to install Kali Linux 2017.1 LXDE on VMware Workstation or VMware Workspace. Kali LXD is a very simple and easy-to-use software that can be installed on your computer. To install it, click o
- 3mo agoRPRXRoyalty Pharma reports second quarter 2026 resultsGlobeNewswirePortfolio Receipts growth of 6% to $773 million; Royalty Receipts growth of 14%Net cash provided by operating activities of $728 millionRaised full year 2026 guidance: Portfolio Receipts expected to be $3,400 million to
- 3mo agoRPRXRoyalty Pharma appoints Greg Raskin as Senior Vice President, Head of Academic InitiativesGlobeNewswireNEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Greg Raskin, M.D. as Senior Vice President, Head of Academic Initiatives, effective August 2026. Greg
- 3mo agoRPRXRoyalty Pharma acquires royalty interest in AstraZeneca’s cliramitug for up to $425 million from NeurimmuneGlobeNewswireNEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it has acquired a portion of Neurimmune’s royalty interest in AstraZeneca’s cliramitug for up to $425 million,
- 3mo agoRPRXRoyalty Pharma declares third quarter 2026 dividendGlobeNewswireNEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (NASDAQ:RPRX) has approved the payment of a dividend for the third quarter of 2026 of $0.235 per Class A ordinary share. The
- 3mo agoRPRXRoyalty Pharma to announce second quarter 2026 financial results on August 5, 2026GlobeNewswireNEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will report its second quarter 2026 financial results on Wednesday, August 5, 2026 before the U.S. financial markets
- 5mo agoRPRXRoyalty Pharma to present at the Goldman Sachs 47th Annual Global Healthcare ConferenceGlobeNewswireNEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9,
- 6mo agoRPRX2026 Global Healthcare Conference - Royalty Pharma PLCEarnings Call TranscriptsOkay. All right, everybody. We're going to get going here with our next company presenter at the B of A Annual Healthcare Conference. My name is Jason Gerber. I cover biotech and pharma, and I am pleased to be introducin
- 6mo agoRPRXRoyalty Pharma to present at upcoming investor conferencesGlobeNewswireNEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: BofA Securities 2026
- 6mo agoRPRXRoyalty Pharma reports first quarter 2026 resultsGlobeNewswirePortfolio Receipts growth of 10% to $925 million; Royalty Receipts growth of 13%Net cash provided by operating activities of $718 millionRaised full year 2026 guidance: Portfolio Receipts expected to be $3,325 million to
- 6mo agoRPRXRoyalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific InnovationGlobeNewswireNEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the launch of the Royalty Pharma Translational Prize, which recognizes exceptional achievements in translational medicine.
- 6mo agoRPRXRoyalty Pharma Declares Second Quarter 2026 DividendGlobeNewswireNEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (NASDAQ:RPRX) has approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A ordinary share. The
- 7mo agoRPRXRoyalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026GlobeNewswireNEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the U.S. financial markets
- 7mo agoRPRXRoyalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated DiseasesGlobeNewswireNEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of $500 million in 2026 and
- 7mo agoRPRXRoyalty Pharma Appoints Lucas Glass as Head of Artificial IntelligenceGlobeNewswireNEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead the development and
- 8mo agoRPRXRoyalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global PlatformGlobeNewswireNEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be based in Hong Kong
- 8mo agoRPRXZYMERoyalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note FinancingGlobeNewswireZymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaidZymeworks to retain 70% of royalties on
- 8mo agoRPRXZYMEZymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note FinancingGlobeNewswireZymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaidZymeworks to retain 70% of royalties on
- 8mo agoRPRXRoyalty Pharma to Present at TD Cowen's 46th Annual Health Care ConferenceGlobeNewswireNEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will participate in a fireside chat at TD Cowen's 46th Annual Health Care Conference on March 3, 2026 at 1:10 p.m.
- 9mo agoRPRXRoyalty Pharma Reports Q4 and Full Year 2025 ResultsGlobeNewswirePortfolio Receipts of $874 million in Q4 2025 and $3,254 million for FY 2025 Portfolio Receipts growth of 18% in Q4 2025 and 16% for FY 2025Net cash provided by operating activities of $827 million in Q4 2025 and
- 9mo agoRPRXRoyalty Pharma to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026GlobeNewswireNEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will report its fourth quarter and full year 2025 financial results on Wednesday, February 11, 2026 before the U.S.
- 10mo agoRPRXRoyalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireRoyalty funding market reached record high of $10 billion in 2025, powered by synthetic royaltiesRoyalty Pharma maintained industry leadership with announced transactions of $4.7 billion Multiple potential value-creating
- 10mo agoRPRXRoyalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for VitiligoGlobeNewswireRoyalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million, to support Teva's anti-IL-15 candidate, TEV-‘408 TEV-‘408 is currently
- 10mo agoRPRXTEVATeva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for VitiligoGlobeNewswireRoyalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding and a Royalty Pharma option for an additional $425 million to support Teva's anti-IL-15 candidate TEV-‘408TEV-‘408 is currently in
- 10mo agoRPRXRoyalty Pharma Announces Dividend IncreaseGlobeNewswireNEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2026 of $0.235 per Class A ordinary share,
- 10mo agoRPRXRoyalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential MilestonesGlobeNewswireNEW YORK, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it has acquired the final portion of PTC Therapeutics' remaining royalty on Roche's Evrysdi for $240 million upfront and
- 11mo agoRPRXRoyalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 MillionGlobeNewswireNEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an undisclosed third
- 11mo agoONCYIMRXTNGXMRNA+1Pancreatic Cancer Survival Gains Accelerate as Novel Therapies AdvancePR NewswireUSANewsGroup.com News Commentary – Scientists developed an antibody treatment that reawakens the immune system to attack pancreatic tumors by...
- 11mo agoDNLIRPRXRoyalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding AgreementGlobeNewswireNEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) and Denali Therapeutics, Inc. (NASDAQ:DNLI) today announced a $275 million synthetic royalty funding
- 11mo agoDNLIRPRXDenali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding AgreementGlobeNewswireSOUTH SAN FRANCISCO, Calif. and NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ:DNLI) and Royalty Pharma plc (NASDAQ:RPRX) today announced a $275 million synthetic royalty funding agreement
- 11mo agoRPRXRoyalty Pharma to Present at Upcoming Investor ConferencesGlobeNewswireNEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December: Citi's 2025 Global
- 1y agoRPRXRoyalty Pharma Reports Third Quarter 2025 ResultsGlobeNewswirePortfolio Receipts growth of 11% to $814 million; Royalty Receipts growth of 11%Net cash provided by operating activities of $703 millionRaised full year 2025 guidance: Portfolio Receipts expected to be $3,200 to $3,250
- 1y agoRPRXRoyalty Pharma Acquires Royalty Interest in Alnylam's AMVUTTRA for $310 Million from Blackstone Life SciencesGlobeNewswireNEW YORK and CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it has acquired a royalty interest in Alnylam's AMVUTTRA from funds managed by Blackstone Life
- 1y agoRPRXRoyalty Pharma Declares Fourth Quarter 2025 DividendGlobeNewswireNEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (NASDAQ:RPRX) has approved the payment of a dividend for the fourth quarter of 2025 of $0.22 per Class A ordinary share. The
- 1y agoRPRXRoyalty Pharma to Announce Third Quarter 2025 Financial Results on November 5, 2025GlobeNewswireNEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will report its third quarter 2025 financial results on Wednesday, November 5, 2025 before the U.S. financial markets
- 1y agoRPRXRoyalty Pharma Appoints Dr. Ted W. Love As Lead Independent DirectorGlobeNewswireNEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ: RPRX) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W.
- 1y agoRPRXRoyalty Pharma to Present at Bernstein's 2nd Annual Healthcare ForumGlobeNewswireNEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will participate in a fireside chat at Bernstein's 2nd Annual Healthcare Forum on Tuesday, September 23, 2025 at
- 1y agoRPRXRoyalty Pharma Plc (RPRX) Investor Day 2025 Call (Transcript)Earnings Call Transcripts
- 1y agoRPRXRoyalty Pharma Plc (RPRX) Investor Day 2025 TranscriptEarnings Call Transcripts
- 1y agoRPRXRoyalty Pharma Investor Day Highlights Strong Growth Outlook and Company's Plans to Drive Value CreationGlobeNewswireOn track to deliver Portfolio Receipts of $4.7 billion or more by 2030, significantly ahead of consensusGoal to achieve at least mid-teens average annual total shareholder return over next 5 years with significant upside